



CKET NO: 17349CIP(HL)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chow et al)
)
Serial No.: Not assigned)
Conf. No.: 9534)
Filed: 10/039,827)
)
For: METHODS AND)
COMPOSITIONS FOR)
MODULATING ALPHA)
ADRENERGIC RECEPTOR)
ACTIVITY)
)
Examiner: Zohreh A. Fay)
)

Group Art Unit: 1614

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Box Supplemental IDS-Non Fee; Commissioner of Patents and Trademarks, Washington, D.C. 20231 on:

Date of Deposit: 2/3/2003
Person making Deposit: BONNIE FERGUSON
Signature: Bonnie Ferguson
Date of Signature: 2/3/2003

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicant herewith submits forms PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR § 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicant makes no admission that any item listed thereupon is material to the patentability of the invention claimed in the above-entitled patent application. Further, Applicant makes no assertion hereby that a search was conducted, or if conducted, that any search was thorough.


Applicant respectfully requests that the Examiner indicate consideration of the presently cited references by returning the enclosed Form 1449 bearing the Examiner's initials and the date considered.

Docket No. 17349CIP(HL)
Serial No. 10/039,827

Each item of information contained in this Supplemental Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.

Dated: 1/3/2003

Respectfully submitted,

By: 
Carlos A. Fisher
Registration No. 36,510
Attorney of Record

Allergan, Inc. (T2-7H)
2525 Dupont Drive
Irvine, CA 92612
Telephone: 714-246-4920
Fax: 714-246-4249